Cancer Markers for Colon, Liver, and Pancreatic Cancer
CEA is the only recommended serum marker for colorectal cancer management, AFP is the primary marker for hepatocellular carcinoma, and CA 19-9 has limited utility for pancreatic cancer monitoring only.
Colorectal Cancer
CEA (Carcinoembryonic Antigen) - The Standard Marker
CEA is the marker of choice for colorectal cancer and should be used in specific clinical scenarios 1:
When to Use CEA:
Preoperative staging: May be ordered if it assists in surgical planning, though elevated levels (>5 ng/mL) correlate with poorer prognosis but should not determine adjuvant therapy decisions 1
Postoperative surveillance: Measure every 3 months for at least 3 years in stage II or III disease, but only if the patient is a candidate for surgery or systemic therapy 1
Monitoring metastatic disease: Measure at treatment start and every 1-3 months during active therapy 1
- Persistently rising values above baseline suggest progressive disease even without radiographic confirmation
- Critical caveat: Exercise caution interpreting rising CEA during the first 4-6 weeks of new therapy, especially after oxaliplatin, as spurious early rises can occur 1
What NOT to Use for Colorectal Cancer:
CA 19-9, p53, ras, DNA ploidy, MSI, TS, DPD, TP, and 18q/DCC are NOT recommended for screening, diagnosis, staging, surveillance, or monitoring treatment 1. The evidence is insufficient across all these markers.
Hepatocellular Carcinoma (Liver Cancer)
AFP (Alpha-Fetoprotein) - Primary Marker
AFP is the most widely used marker for HCC with 60% sensitivity and 90% specificity 2:
AFP-L3 (Lens culinaris agglutinin-reactive fraction): When AFP-L3 comprises >10% of total AFP, it is highly specific for small HCC 2
PIVKA-II/DCP (Des-gamma-carboxy prothrombin): More specific than total AFP for detecting HCC 2
The combination of all three markers (AFP, AFP-L3, and PIVKA-II) provides the best diagnostic accuracy since their levels are independent of each other 3, 2. These markers correlate with:
- Disease progression at diagnosis
- Tumor aggressiveness
- Treatment responsiveness
- Recurrence monitoring
- Patient survival 3
Important Limitation:
While AFP is the standard, newer markers like glypican-3 are under investigation but not yet validated for routine clinical use 2.
Pancreatic Cancer
CA 19-9 - Limited Utility
CA 19-9 has very restricted clinical utility for pancreatic cancer 1, 4:
What CA 19-9 Should NOT Be Used For:
- NOT for screening 1
- NOT for determining operability alone 1
- NOT as definitive evidence of recurrence without imaging confirmation 1
Limited Acceptable Use:
CA 19-9 can be measured every 1-3 months during active treatment for locally advanced or metastatic disease 1:
- Measure at treatment start
- Rising serial CA 19-9 may indicate progressive disease but requires confirmation with imaging studies 1
- Can be used to measure disease burden and potentially guide treatment decisions 4
Critical Context:
The 2023 ESMO guidelines note that CA 19-9 >500 IU/ml is considered a biological factor in borderline resectable disease, but this is part of a multidimensional assessment including anatomical and conditional factors 4.
Key Clinical Pitfalls to Avoid
Never start systemic therapy based on CEA elevation alone - always confirm with imaging 1
Don't misinterpret early CEA rises during chemotherapy - particularly in the first 4-6 weeks with oxaliplatin 1
All CEA analyses for a given patient must be performed in the same laboratory using the same technique to ensure consistency 5
CA 19-9 cannot be used alone for pancreatic cancer management - it must be combined with imaging and clinical findings 1
Don't use AFP alone for HCC - combination with AFP-L3 and PIVKA-II significantly improves diagnostic accuracy 3, 2